ClinicalTrials.gg

Program

PRMT5 Inhibitor BAY 3713372

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Bayer.

Furthest: phase 2, since Mar 31, 20251 company-led study, 1 open or runningNext primary completion: Jun 18, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer11 open or runningphase 2since Mar 31, 2025Mar 31, 2025Jun 18, 2029phase 2 · NCT06914128

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06914128 · 450 planned · United States, Australia, Belgium and more

Ahead

  1. Jun 18, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06914128

TargetBeta

PRMT5 →read by rule
“An orally bioavailable, blood-brain-barrier (BBB) penetrating, methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06914128Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2RecruitingJun 18, 2029450

How it is read

Names in the registry

  • “BAY 3713372”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.